Stem cells

BioCardia to Participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference on August 10, 2021

Retrieved on: 
Wednesday, August 4, 2021
Stem cells

For those unable to attend, a replay of the presentation will be available until the end of the day Tuesday, August 10, 2021 on the BTIG conference website .

Key Points: 
  • For those unable to attend, a replay of the presentation will be available until the end of the day Tuesday, August 10, 2021 on the BTIG conference website .
  • You must be a BTIG client to attend and access the replay.
  • BioCardia, Inc. , headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and pulmonary disease.
  • CardiAMP autologous and NK1R+ allogeneic cell therapies are the Companys biotherapeutic product candidates in clinical development.

Asia-Pacific Cell Therapy Market Analysis Report 2021-2028 by Use-type (Clinical-use, Research-use), & Therapy Type (Autologous, Allogeneic) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 4, 2021
Health, Biotechnology, Life sciences, Health sciences, Branches of biology, Stem cells, Biotechnology, Drug discovery, Medicinal chemistry, Therapy, Cell therapy, SWOT analysis

The "Asia Pacific Cell Therapy Market Size, Share & Trends Analysis Report by Use-type (Clinical-use, Research-use), by Therapy Type (Autologous, Allogeneic) and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia Pacific Cell Therapy Market Size, Share & Trends Analysis Report by Use-type (Clinical-use, Research-use), by Therapy Type (Autologous, Allogeneic) and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Asia Pacific cell therapy market size is expected to reach USD 2.9 billion by 2028.
  • The market is expected to expand at a CAGR of 14.9% from 2021 to 2028.
  • Chapter 3 Cell Therapy Market Variables, Trends, and Scope
    3.4 Penetration and Growth Prospect Mapping for Therapy Type, 2020
    3.5.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
    Chapter 4 Cell Therapy Market: COVID-19 Impact analysis

Gamida Cell Announces the Date of Its Second Quarter 2021 Financial Results and Webcast

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Health, Stem Cells, Pharmaceutical, Oncology, Branches of biology, Biology, Immune system, Lymphocytes, Medical specialties, Biotechnology, Natural killer cell, Stem cells, Leukemia, Chimeric antigen receptor T cell

ET to review its second quarter 2021 financial results and provide an update on the company.

Key Points: 
  • ET to review its second quarter 2021 financial results and provide an update on the company.
  • Gamida Cell will also provide an update on its pipeline of NAM-enabled natural killer (NK) cell therapies, including GDA-201 and genetically-modified NK cell constructs.
  • The webcast will be available on the Investors & Media section of the Gamida Cell website at www.gamida-cell.com .
  • Gamida Cell is an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases.

Live Cell Imaging Global Market Report 2021: COVID-19 Growth and Change to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 3, 2021
Medical devices, Health, Radiology, Stem cells, Medical Supplies, COVID-19, Occupational safety and health, Public health, Zoonoses, Health, Medical specialties

The "Live Cell Imaging Global Market Report 2021: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Live Cell Imaging Global Market Report 2021: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • Live Cell Imaging Global Market Report 2021: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global live cell imaging market.
  • The global live cell imaging market is expected to grow from $3.61 billion in 2020 to $3.98 billion in 2021 at a compound annual growth rate (CAGR) of 10.3%.
  • The live cell imaging market consists of sales of live cell imaging by entities (organizations, sole traders, and partnerships) that are engaged in manufacturing and selling live cell imaging equipment and consumables.

Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, August 3, 2021
Research, FDA, Clinical trials, Stem cells, Biotechnology, Health, Pharmaceutical, Other Science, Science, Economy of New York City, NASDAQ, Chief financial officer, Business, Finance, Economy

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome company developing a novel class of multifunctional bacterial therapeutics designed to functionally interact with host cells and tissues to treat disease, today reported second quarter 2021 financial results and provided business updates.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome company developing a novel class of multifunctional bacterial therapeutics designed to functionally interact with host cells and tissues to treat disease, today reported second quarter 2021 financial results and provided business updates.
  • Appointment of Chief Financial Officer and Head of Business Development: In May, Seres announced that David Arkowitz was appointed as Executive Vice President, Chief Financial Officer (CFO) and Head of Business Development.
  • Research and development expenses for the second quarter of 2021 were $36.0 million, compared with $20.1 million for the same period in 2020.
  • General and administrative expenses for the second quarter of 2021 were $17.5 million, compared with $6.5 million for the same period in 2020.

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, Health, Genetics, Stem cells, Oncology, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Induced stem cells, Cloning, Developmental biology, Hematopoietic stem cell transplantation, Organ transplantation, Regenerative Medicine Advanced Therapy

Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following August investor conferences:

Key Points: 
  • Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following August investor conferences:
    2021 Wedbush PacGrow Healthcare Virtual Conference, panel: So Let it Be (Re)Written - Updates in Gene Modulation at 9:10 a.m.
  • ET on Tuesday, August 10
    Magenta Therapeutics is a clinical-stage biotechnology company developing medicines designed to bring the curative power of stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases.
  • Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.
  • Magenta is based in Cambridge, Mass.

Resolve Biosciences and ZEISS Announce Co-Development Collaboration to Enhance Highest-Resolution View of Subcellular Spatial Biology

Retrieved on: 
Tuesday, August 3, 2021
Software, Research, Hardware, Data management, Oncology, Technology, Infectious diseases, Genetics, Science, Nanotechnology, Biotechnology, Stem cells, Health, Spatial analysis, ZEISS, Resolve Biosciences, ZEISS, RESOLVE BIOSCIENCES

Resolve Biosciences, the pioneer in Molecular Cartography, and ZEISS today announced a co-development collaboration to advance spatial biology applications.

Key Points: 
  • Resolve Biosciences, the pioneer in Molecular Cartography, and ZEISS today announced a co-development collaboration to advance spatial biology applications.
  • Through this collaboration, ZEISS and Resolve Biosciences will combine leading optical technologies and engineering expertise with multi-analyte and highly multiplexed spatial analysis to illuminate molecular interactions at subcellular resolution while preserving the sample tissue.
  • We are committed to working with the Resolve team to allow more researchers to gain new insights in subcellular spatial biology.
  • Resolve Biosciences is applying the power of Molecular Cartography to enable scientists to gain new insights based on the highest-resolution view of spatial biology.

Gamida Cell to Present at the BTIG Virtual Biotechnology Conference

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, Health, Stem cells, Pharmaceutical, Oncology, Branches of biology, Stem cells, Biology, Medical specialties, Biotechnology, Cell biology, Hematopoietic stem cell transplantation, Lymphology, Transplantation medicine, Cell therapy

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 10, 2021 at 3:00 p.m.

Key Points: 
  • Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 10, 2021 at 3:00 p.m.
  • In the fourth quarter of 2021, Gamida Cell is targeting a BLA submission for omidubicel, the first potential approval of a cell therapy for blood cancer patients in need of an allogeneic bone marrow transplant.
  • Gamida Cell is an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases.
  • For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn or Twitter at @GamidaCellTx.

Cellino Appoints Industry Pioneer Robert J. Palay to the Board

Retrieved on: 
Tuesday, August 3, 2021
Technology, Surgery, Medical devices, General Health, Science, Genetics, Biotechnology, Health, Other Science, Research, Other Technology, Software, Other Health, Hardware, Pharmaceutical, Stem cells, Oncology, Branches of biology, Biology, Life sciences, Induced stem cells, Stem cells, Biotechnology, Cloning, Developmental biology, Induced pluripotent stem cell, Cellino, IPSC

Cellino , a personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, today announced the appointment of industry pioneer Robert J. Palay, J.D., M.B.A., to the Cellino Board of Directors.

Key Points: 
  • Cellino , a personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, today announced the appointment of industry pioneer Robert J. Palay, J.D., M.B.A., to the Cellino Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20210803005032/en/
    Mr. Palay is one of the pioneers of the induced pluripotent stem cell (iPSC) industry.
  • "We are pleased to welcome Robert to the Cellino Board," said Nabiha Saklayen, Ph.D, CEO & Co-Founder, Cellino.
  • "I am thrilled to join the Cellino Board," said Robert J. Palay.

Tango Therapeutics to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, Health, Oncology, Stem cells

Tango Therapeutics Inc., a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, MD, President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a panel on synthetic lethality in cancer therapeutics at the 12th Annual Wedbush PacGrow Healthcare Conference on Tuesday, August 10 at 11:30 AM ET.

Key Points: 
  • Tango Therapeutics Inc., a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, MD, President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a panel on synthetic lethality in cancer therapeutics at the 12th Annual Wedbush PacGrow Healthcare Conference on Tuesday, August 10 at 11:30 AM ET.
  • A live webcast of the event will be available under the "Events & Presentations" tab on the Investors page on the Company's website on the day of the event.
  • A replay of the webcast will be archived on the Company's website for 30 days following the presentation.
  • Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.